Peter Nash

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 54

Top Venues

RMD open

Annals of the rheumatic diseases

The Journal of rheumatology

Rheumatology (Oxford, England)

Griffith University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Griffith University

Australia

Professor :: Medicine

University of Queensland Jun 30 2008

Australia

Associate Professor :: Medicine

Rheumatology Department, Sunshine Coast University Hospital Jan 08 1989

Australia

Senior Rheumatologist :: Rheumatology

Rheumatology Research Unit Nov 08 1988

Australia

Director

Publications

Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet E Pope, Georg Pongratz, Bruno Fautrel, Rieke E Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD open 10 (1) (2024)
Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet E Pope, Georg Pongratz, Bruno Fautrel, Rieke E Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD open 10 (1) (2024)
Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet E Pope, Georg Pongratz, Bruno Fautrel, Rieke E Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD open 10 (1) (2024)
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Phillip J Mease, Philip S Helliwell
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD open 10 (1) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Atul A Deodhar, Xenofon Baraliakos, Marina Magrey, Lianne S Gensler, Amit V Thorat, Surya Kiran Pemmaraju, Mary Jane Cadatal, Peter Nash
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials. The Journal of rheumatology 51 (8) (2024)
Phillip J Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, Laura C Coates
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford, England) 63 (7) (2024)
Arthur Kavanaugh, Phillip J Mease, Laure Gossec, Roberto Ranza, Shigeyoshi Tsuji, Kevin Douglas, Michael Lane, Ralph Lippe, Manish Mittal, Tianming Gao, Arathi Setty, Sandra Ciecinski, Daniel Aletaha, Peter Nash
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials. ACR open rheumatology (2024)
Atul A Deodhar, Xenofon Baraliakos, Marina Magrey, Lianne S Gensler, Amit V Thorat, Surya Kiran Pemmaraju, Mary Jane Cadatal, Peter Nash
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials. The Journal of rheumatology (2024)
Atul A Deodhar, Xenofon Baraliakos, Marina Magrey, Lianne S Gensler, Amit V Thorat, Surya Kiran Pemmaraju, Mary Jane Cadatal, Peter Nash
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials. The Journal of rheumatology 51 (8) (2024)
Phillip J Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, Laura C Coates
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford, England) 63 (7) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Phillip J Mease, Philip S Helliwell
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD open 10 (1) (2024)
Phillip J Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, Laura C Coates
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford, England) 63 (7) (2024)
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Phillip J Mease, Philip S Helliwell
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD open 10 (1) (2024)
Peter Nash
JAK inhibitors: new indication and emerging safety data in 2022. Nature reviews. Rheumatology 19 (2) (2023)
Peter Foley, Kurt Gebauer, John R Sullivan, Erin K McMeniman, Stephen Shumack, Jonathan Ng, Amelia C James, Morton Rawlin, Shireen Sidhu, Dev Tillakaratne, Murray Turner, Barbara Radulski, Peter Nash, Christopher Baker
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patients. The Australasian journal of dermatology (2023)
Phillip J Mease, Peter Nash, Suzanne M Dolwick Grieb, Vinod Chandran
Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis. The Journal of rheumatology (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Peter Nash
JAK inhibitors: new indication and emerging safety data in 2022. Nature reviews. Rheumatology 19 (2) (2023)
Peter Nash, Jan P Dutz, Steve Peterson, Barkha P Patel, Kiefer Eaton, May Shawi, Federico Zazzetti, James Cheng-Chung Wei
Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes. BMJ open 13 (11) (2023)
Beverly Cheok Kuan Ng, Deepak R Jadon, Adewale O Adebajo, Gizem Ayan, Kristina Callis Duffin, Vinod Chandran, Laura C Coates, Maria Antonietta D'Agostino, Kurt de Vlam, Atul A Deodhar, Lihi Eder, Amit Garg, Dafna D Gladman, Niti Goel, Alice B Gottlieb, M Elaine Husni, Arnon M Katz, Arthur Kavanaugh, Ennio Lubrano, Phillip J Mease, Joseph Frank Merola, Peter Nash, Philip S Helliwell, Stephen R Pennington, Lourdes Maria Perez-Chada, Fabian Proft, Cheryl F Rosen, Laura Savage, Cláudia Goldenstein-Schainberg, Stefan Siebert, Enrique Roberto Soriano, Ingrid Steinkoenig, William Tillett, April W Armstrong, Oliver M FitzGerald
Proceedings of the GRAPPA 2022 Executive Retreat. The Journal of rheumatology (2023)
Christina Charles-Schoeman, Ernest H S Choy, Iain B McInnes, Eduardo Mysler, Peter Nash, Kunihiro Yamaoka, Ralph Lippe, Nasser Khan, Anna K Shmagel, Hannah Palac, Jessica Suboticki, Jeffrey R Curtis
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD open 9 (4) (2023)
Elena Nikiphorou, Peter Nash
Comorbidities in RA: bringing them to the limelight. Rheumatology (Oxford, England) 62 (SI3) (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Peter Nash
Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis. The Journal of rheumatology 49 (6 Suppl 1) (2022)
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja Alexandra Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée Mfm van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes W J Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H S Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten P T de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimmie L Hyrich, AnnaMaria Iagnocco, John Dudley Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the rheumatic diseases (2022)
Ennio Lubrano, Jonathan Chan, Rubén Queiro, Alberto Cauli, Niti Goel, Denis Poddubnyy, Peter Nash, Dafna D Gladman
Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. The Journal of rheumatology (2022)
Hoi Ki Joshua Tam, Philip C Robinson, Peter Nash
Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms. Current rheumatology reports 24 (10) (2022)
Peter Nash
JAK inhibitors: new indication and emerging safety data in 2022. Nature reviews. Rheumatology (2022)
Josef S Smolen, Robert B M Landewe, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimmie L Hyrich, Janet E Pope, Savia de Souza, Tanja Alexandra Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L Winthrop, Alejandro Balsa, Joan M Bathon, Maya H Buch, Gerd-Rüdiger R Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques-Eric Gottenberg, Espen A Haavardsholm, AnnaMaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B McInnes, Eduardo F Mysler, Peter Nash, Gyula Poor, Gorica G Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Thea P M Vliet Vlieland, René Westhovens, Désirée Mfm van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the rheumatic diseases (2022)
Effie Pournara, Matthias Kormaksson, Peter Nash, Christopher T Ritchlin, Bruce W Kirkham, Gregory Ligozio, Luminita Pricop, Alexis Ogdie, Laura C Coates, Georg Schett, Iain B McInnes
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD open 7 (3) (2022)
Peter Nash, Pascal Richette, Laure Gossec, Antonio Marchesoni, Christopher Ritchlin, Koji Kato, Erin L McDearmon-Blondell, Elizabeth Lesser, Reva McCaskill, Dai Feng, Jaclyn K Anderson, Eric M Ruderman
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford, England) (2021)
Bernard G Combe, Alan Kivitz, Yoshiya Tanaka, Désirée Mfm van der Heijde, J Abraham Simon, Herbert S B Baraf, Uma Kumar, Franziska Matzkies, Beatrix Bartok, Lei Ye, Ying Guo, Chantal Tasset, John S Sundy, Angelika Jahreis, Mark C Genovese, Neelufar Mozaffarian, Robert B M Landewe, Sang-Cheol Bae, Edward C Keystone, Peter Nash
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the rheumatic diseases 80 (7) (2021)
Peter Nash
Clinical use of Jak 1 inhibitors for rheumatoid arthritis. Rheumatology (Oxford, England) 60 (Suppl 2) (2021)
Peter Nash, Josef S Smolen
Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday et al. Annals of the rheumatic diseases (2021)
Kevin L Winthrop, Peter Nash, Kunihiro Yamaoka, Eduardo Mysler, Nasser Khan, Heidi S Camp, Yanna Song, Jessica L Suboticki, Jeffrey R Curtis
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Annals of the rheumatic diseases (2021)
Janet E Pope, Peter Nash, Roy M Fleischmann
Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail! Arthritis & rheumatology (Hoboken, N.J.) 73 (7) (2021)
Andreas Kerschbaumer, Josef S Smolen, Peter Nash, Thomas Dörner, Maxime Dougados, Roy M Fleischmann, Klaus Geissler, Iain B McInnes, Tsutomu Takeuchi, Michael Trauner, Kevin Winthrop, Maarten P T de Wit, Wolf-Henning Boehncke, Louise Falzon, Désirée Mfm van der Heijde
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD open 6 (3) (2021)
Gerd R Burmester, Peter Nash, Bruce E Sands, Kim Papp, Lori Stockert, Thomas V Jones, Huaming Tan, Ann Madsen, Hernan Valdez, Stanley B Cohen
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD open 7 (2) (2021)
Hoi Ki Joshua Tam, Peter Nash, Philip C Robinson
The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels. ACR open rheumatology 3 (10) (2021)
Stanley B Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R Curtis, Eun Bong Lee, Peter Nash, Kevin L Winthrop, Christina Charles-Schoeman, Lisy Wang, Connie Chen, Kenneth Kwok, Pinaki Biswas, Andrea Shapiro, Ann Madsen, Jürgen Wollenhaupt
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD open 6 (3) (2021)
Peter Nash
2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews. Annals of the rheumatic diseases 79 (6) (2020)
Josef S Smolen, Philip Mease, Hasan Tahir, Hendrik Schulze-Koops, Inmaculada de la Torre, Lingnan Li, Maja Hojnik, Christophe Sapin, Masato Okada, Roberto Caporali, Jordi Gratacós, Philippe Goupille, Soyi Liu Leage, Sreekumar Pillai, Peter Nash
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Annals of the rheumatic diseases 79 (10) (2020)
Peter Nash
How Can We Improve the Use of Established Therapies in PsA? The Journal of rheumatology 47 (8) (2020)
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, Maxime Dougados, Roy M Fleischmann, Klaus Geissler, Iain McInnes, Janet E Pope, Désirée Mfm van der Heijde, Michaela Stoffer-Marx, Tsutomu Takeuchi, Michael Trauner, Kevin L Winthrop, Maarten P T de Wit, Daniel Aletaha, Xenofon Baraliakos, Wolf-Henning Boehncke, Paul Emery, John D Isaacs, Joel Kremer, Eun Bong Lee, Walter P Maksymowych, Marieke Voshaar, Lai-Shan Tam, Yoshiya Tanaka, Filip van den Bosch, René Westhovens, Ricardo Xavier, Josef S Smolen
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the rheumatic diseases 80 (1) (2020)
Phillip J Mease, Ernest H S Choy, Peter Nash, Chrysostomos Kalyvas, Matthias Hunger, Luminita Pricop, Kunal K Gandhi, Steffen M Jugl, Howard H Z Thom
Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. European journal of rheumatology 6 (3) (2018)
Walter P Maksymowych, Vibeke Strand, Peter Nash, Yusuf Yazici, Howard H Z Thom, Matthias Hunger, Chrysostomos Kalyvas, Kunal K Gandhi, Brian Porter, Steffen M Jugl
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. European journal of rheumatology 5 (4) (2018)

Peter Nash.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Peter Nash